By Helena Smolak
Bayer is discontinuing early a Phase 3 study to test investigational drug asundexian on prevention of stroke and systemic embolism for patients with atrial fibrillation due to lack of efficacy.
The German pharmaceutical-and-agricultural group said late Sunday that the decision is based on a recommendation by the independent…
Read the full article here
